Alvotech to Participate in September Investor Conferences
Biotechnology company Alvotech announced its participation in two investor conferences in September, focusing on its biosimilar medicines.
Alvotech, a global biotechnology company focused on developing and manufacturing biosimilar medicines, has announced its participation in two upcoming investor conferences in September. Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will represent the company at these events.
The conferences provide Alvotech with an opportunity to present its business and future outlook to investors in the healthcare sector. The company's core mission is to deliver high-quality, cost-effective biosimilar products for patients worldwide.
Alvotech is scheduled to participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. Following this, the company will host investor meetings at Deutsche Bank's 2026 Healthcare Summit on September 17. Both events are taking place in New York. A live webcast of the fireside chat will be accessible via Alvotech's website.
The company currently has several approved biosimilars on the market, targeting conditions such as autoimmune disorders and eye conditions. Alvotech has established strategic commercial partnerships to ensure global reach for its products.